MarketPulse
V

$VERA

4 articles found
3 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

IgA Nephropathy Market Set to Nearly Quadruple by 2036 Amid Novel Therapy Wave

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.
NVSVRTXRHHBYAZNTAK+4clinical trialsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Idiopathic Membranous Nephropathy Market Poised to Hit $1B by 2036

IMN market expected to grow nearly 8x from $130M in 2025 to $1B by 2036, driven by novel therapies addressing unmet treatment needs.
NKTXVRTXRHHBYAZNBIIB+2clinical trialspharmaceutical pipeline
The Motley FoolThe Motley Fool··Jonathan Ponciano

Deerfield Doubles Down on Vera Therapeutics as Kidney Drug Nears FDA Decision

Deerfield Management increases Vera Therapeutics stake to $205.58M as kidney drug atacicept approaches July 7 FDA decision. Stock up 50% annually.
VERAFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Vera Therapeutics Bolsters Board with Royalty Pharma Executive Ahead of Key Drug Launch

Vera Therapeutics appoints Christopher Hite, Royalty Pharma EVP, to board as the biotech prepares for atacicept launch in IgA nephropathy treatment.
RPRXVERAbiopharmaceuticalIgA nephropathy